Next-Generation IVD Market Share Growth

2025

2030

Global Next-Generation IVD Market – Analysis and Forecast (2025-2030)

Industry Insight by Type (core laboratory diagnostics, POC testing, and molecular diagnostics), by Product Type (consumables, instruments, and software), by Application (oncology/cancer, infectious diseases, diabetes, cardiology, and other applications), by End-use Industry (hospitals and clinics, diagnostic laboratories, academic and research institutions, and other end-use industries), and Geography (U.S., Canada, Germany, U.K., France, China, Japan, India, and Rest of the World)

Ask for Customization

Request for Sample

Industry Overview

Next-Generation In Vitro Diagnostics (IVD) refers to advanced technologies and methodologies that revolutionize diagnostic testing outside the human body. It encompasses cutting-edge approaches like molecular diagnostics, genomics, proteomics, and digital pathology, enabling more precise and personalized healthcare. Next-Generation IVD enhances disease detection, monitoring, and treatment by providing rapid, accurate, and comprehensive insights into an individual's health. These innovations empower healthcare professionals to tailor interventions, predict disease risks, and optimize therapeutic strategies, marking a significant leap forward in the field of diagnostics for improved patient outcomes and healthcare efficiency.

Next-Generation IVD Market

Global next-generation IVD market was worth USD 87.40 billion in 2023 and is expected reach USD 125.00 billion by 2030 with a CAGR of 5.11% during the forecast period, i.e., 2025-2030. The growing demand for next-generation IVD is driven by the advancements in genomics and molecular diagnostics, increasing demand for personalized medicine, a focus on early disease detection, and the rise of digital health technologies for more precise and efficient diagnostic capabilities.

Geographically, the global next-generation IVD market is expanding rapidly in North America, Europe, and the Asia Pacific, as a result of the robust healthcare infrastructure, increasing adoption of advanced diagnostic technologies, rising awareness of personalized medicine, and supportive regulatory frameworks; however, the market confronts constraints such as regulatory complexities, reimbursement issues, and the need for standardization. Overall, the next-generation IVD market offers potential prospects for market participants to develop and fulfill the growing needs of wide range of applications including hospitals and clinics, diagnostic laboratories, academic and research institutions.

Next-Generation IVD Market Segmentation

Insight by Type

Based on type, the global next-generation IVD market is segmented into core laboratory diagnostics, POC testing, and molecular diagnostics. Core laboratory diagnostics dominated the next-generation IVD market in 2023 owing to their essential role in routine clinical testing. These labs offer comprehensive services, integrating advanced technologies for precise and high-throughput analysis. For instance, as of my last knowledge update in January 2023, Roche's cobas 6800/8800 systems, introduced in 2014, exemplify core lab dominance, enabling simultaneous testing of multiple pathogens. Additionally, Siemens Healthineers' Atellica Solution, launched in 2017, integrates various diagnostic disciplines. The scalability, efficiency, and broad testing capabilities of such systems highlight their pivotal role, contributing to the dominance of core laboratory diagnostics in the evolving IVD landscape.

Insight by Product Type

Based on product type, the global next-generation IVD market is segmented into consumables, instruments, and software. Consumable panels dominated the global next-generation IVD market in 2022 as they offer cost-effective and scalable solutions for routine testing. Latest examples include Bio-Rad's ddPCR Multiplex Supermix, launched in 2021, providing precise and multiplexed DNA analysis. Additionally, Illumina's TruSight Oncology 500, introduced in 2020, is a comprehensive panel for cancer profiling. These consumable panels enhance efficiency, reduce turnaround times, and enable targeted analysis. The market dominance of consumable panels is underscored by their adaptability across various diagnostic platforms, facilitating widespread adoption and contributing to the dynamic evolution of the next-generation IVD market.

Insight by Application

Based on application, the global next-generation IVD market is segmented into oncology/cancer, infectious diseases, diabetes, cardiology, and other applications. Oncology/cancer segment dominated the global next-generation IVD market in 2023 due to the increasing demand for precision medicine in cancer treatment. Recent examples include Foundation Medicine's FoundationOne Liquid CDx, approved in 2020, which analyzes circulating tumor DNA for comprehensive genomic profiling. Guardant Health's Guardant360, continually updated, is another example, utilizing liquid biopsy for real-time cancer monitoring. The focus on personalized oncology therapies and the rising incidence of cancer globally drives the prominence of oncology in the next-generation IVD market, reflecting the crucial role these diagnostics play in tailoring treatments and improving patient outcomes.

Insight by End-use Industry

Based on end-use industry, the global next-generation IVD market is segmented into hospitals and clinics, diagnostic laboratories, academic and research institutions, and other end-use industries. Hospitals and clinic dominated the global next-generation IVD market in 2023 as they serve as primary hubs for patient diagnostics and healthcare delivery. The demand for advanced diagnostic capabilities is exemplified by Abbott's Alinity-m molecular diagnostics system, launched in 2020, providing comprehensive infectious disease testing. Additionally, Sysmex Corporation's XN-3100, introduced in 2021, enhances hematology diagnostics in clinical settings. The growing patient influx, coupled with the need for rapid and accurate results, underscores the pivotal role of hospitals and clinics in driving the adoption of next-generation IVD technologies, ensuring effective disease management and improved patient care.

Global Next-Generation IVD Market Report Coverage

Report Metric	Details
Historical Period	2018 - 2023
Base Year Considered	2024
Forecast Period	2025 - 2030
Market Size in 2023	U.S.D. 87.40 Billion
Revenue Forecast in 2030	U.S.D. 125 Billion
Growth Rate	5.11%
Segments Covered in the Report	By Type, By Product Type, By Application and By End-Use Industry
Report Scope	Market Trends, Drivers, and Restraints; Revenue Estimation and Forecast; Segmentation Analysis; Impact of COVID-19; Companies’ Strategic Developments; Market Share Analysis of Key Players; Company Profiling
Regions Covered in the Report	North America, Europe, Asia-Pacific, Middle East, and South America

Industry Dynamics

Next-Generation IVD Market Growth Drivers

Increasing Emphasis on Early Disease Detection and Preventive Healthcare

A significant driver for the growth of the global next-generation in vitro diagnostics (IVD) market is the increasing emphasis on early disease detection and preventive healthcare. Illumina's introduction of the Grail Galleri test in 2021 exemplifies this trend. Galleri is a multi-cancer early detection blood test designed to identify more than 50 types of cancers at an early, potentially curable stage. This reflects a paradigm shift toward proactive healthcare strategies, aligning with the global push for precision medicine and personalized treatment approaches. The ability of such tests to detect multiple cancer types simultaneously and at early stages enhances the prospects for successful intervention, fostering a broader adoption of Next-Generation IVD in routine clinical practice.

Furthermore, the integration of CRISPR technology in diagnostics, demonstrated by Sherlock Biosciences' Sherlock CRISPR SARS-CoV-2 kit, authorized for Emergency Use in 2020, showcases the market's response to emerging infectious threats. The demand for rapid, accurate, and multiplexed diagnostics, particularly in the context of infectious diseases, propels the growth of Next-Generation IVD, emphasizing its crucial role in global health preparedness and response.

Integration of Artificial Intelligence (AI) and Machine Learning (ML) in Diagnostics

The integration of Artificial Intelligence (AI) and Machine Learning (ML) in diagnostics is a key driver for the growth of the global Next-Generation In Vitro Diagnostics (IVD) market. These technologies enhance the accuracy, efficiency, and personalization of diagnostic processes. For instance, Paige Prostate, introduced in 2021, employs AI for pathology interpretation, aiding in prostate cancer diagnosis. Tempus' Tempus ONE, launched in 2020, utilizes ML to streamline clinical workflows and improve cancer care. These platforms leverage large datasets to identify patterns and correlations that may be imperceptible to human analysis, enabling more precise diagnostics and treatment decisions.

The continual evolution of AI and ML applications in diagnostics is catalyzing innovation, driving the adoption of Next-Generation IVD technologies, and revolutionizing the landscape of medical diagnostics for improved patient outcomes and healthcare efficiency. For instance, PathAI, in collaboration with Bristol Myers Squibb, employs AI-powered pathology solutions to improve diagnostic accuracy and efficiency. This amalgamation of cutting-edge technologies not only enhances diagnostic precision but also underscores the transformative potential of next-generation IVD in reshaping healthcare by enabling more proactive and personalized approaches to disease management.

Next-Generation IVD Market Challenge

End-of-Life Management of Next-Generation IVD

One significant challenge for the next-generation IVD industry is the need for standardization and regulatory harmonization. Differing regulations across regions create complexities in product development, approval processes, and market access. Achieving global standardization is critical for ensuring the seamless integration of advanced diagnostic technologies, fostering innovation, and addressing regulatory uncertainties. Overcoming these challenges is essential to facilitate the widespread adoption of next-generation IVD solutions and unlock their full potential in enhancing healthcare outcomes on a global scale.

Next-Generation IVD Market Geographic Overview

North America
Europe
Asia Pacific (APAC)
Middle East and Africa (MEA)
South America

The global next-generation IVD market is segmented into North America, Europe, the Asia-Pacific, South America, and the Middle East and Africa region. The global next-generation IVD market was dominated by North America in 2023 due to its robust healthcare infrastructure, technological advancements, and strategic investments. The region is at the forefront of adopting innovative diagnostic solutions. For instance, Exact Sciences' Cologuard, FDA-approved in 2014, revolutionizes colorectal cancer screening through non-invasive methods. Additionally, Illumina's NovaSeq 6000, launched in 2017, exemplifies cutting-edge genomic sequencing. The region's proactive approach in integrating these technologies into clinical practice, coupled with favorable regulatory frameworks, positions North America as a leader in driving the growth and adoption of next-generation IVD technologies.

Next-Generation IVD Market Competitive Insight

Roche holds a prominent position in the next-generation in vitro diagnostics (IVD) market, continually innovating to advance diagnostic capabilities. Notably, the Cobas 6800/8800 systems, introduced in 2014, exemplify Roche's commitment to high-throughput molecular diagnostics, enabling simultaneous testing for multiple pathogens. The system has been pivotal, especially during the COVID-19 pandemic, showcasing Roche's adaptability to emerging healthcare needs. Roche's leadership extends to personalized medicine with Foundation Medicine, a subsidiary, offering comprehensive genomic profiling services. Through these initiatives, Roche remains a key player driving advancements in the next-generation IVD landscape and contributing significantly to the evolution of diagnostic technologies.

Abbott Laboratories is another major player in the Next-Generation In Vitro Diagnostics (IVD) market, known for its innovative solutions. The approval of the Abbott RealTime SARS-CoV-2 assay in 2020 showcased the company's rapid response to the COVID-19 pandemic, providing reliable diagnostic tools. Abbott's Alinity m molecular diagnostics system, launched in 2020, exemplifies its commitment to high-throughput and comprehensive infectious disease testing. The system offers versatility and efficiency in clinical settings. Abbott's strategic focus on cutting-edge diagnostics positions it as a key contributor to advancements in the Next-Generation IVD market, addressing critical healthcare challenges with innovative solutions.

Recent Development by Key Players

In November 2023, Veracyte and Illumina entered a multi-year agreement to develop decentralized in vitro diagnostic (IVD) tests using Illumina’s NextSeq 550Dx next-generation sequencing instrument. This collaboration, part of Veracyte’s multi-platform IVD approach, is aiming to enhance worldwide accessibility of tests like the Percepta Nasal Swab (for diagnosing lung nodules in smokers) and the Prosigna Breast Cancer Assay. Leveraging quantitative polymerase chain reaction (qPCR) and Illumina's technology, the partnership underscores a commitment to advancing diagnostic capabilities, particularly in noninvasive cancer detection and personalized breast cancer treatment decision-making.

In April 2023, Waters Corporation introduced the Xevo TQ Absolute IVD mass spectrometer, an advanced addition to its MassTrak IVD LC-MS/MS Systems for clinical diagnostics. Boasting up to five times greater sensitivity than comparable instruments, it facilitates the precise quantification of clinical analytes, allowing detection at unprecedented low levels. This innovation supports expanded testing capabilities, including less invasive assays like saliva and dried blood spots, making it especially suitable for hospital and commercial labs aiming for sustainability and growth.

Key Players Covered in the Report

Abbott Laboratories, Becton, Dickinson and Company, bioMérieux SA, Bio-Rad Laboratories, Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd., Illumina, Inc., QIAGEN N.V., Shenzhen Mindray Bio-Medical Electronics Co., Ltd, Siemens Healthineers AG, Thermo Fisher Scientific Inc., Wama Diagnostica, Wiener Laboratorios SAIC, QuidelOrtho Corporation, Agilent Technologies Inc., and DiaSorin S.p.A.

The Next-generation IVD market report offers a comprehensive market segmentation analysis along with an estimation for the forecast period 2025–2030.

Segments Covered in the Report

By Type

Laboratory Diagnostics
POC Testing
Molecular Diagnostics

By Product Type

Consumables
Instruments
Software

By Application

Oncology/Cancer
Infectious Diseases
Diabetes
Cardiology
Other Applications

By End-Use Industry

Hospitals and Clinics
Diagnostic Laboratories
Academic and Research Institutions
Other end-use industry

Region Covered in the Report

North America

U.S.
Canada
Mexico

Europe

Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe

Asia-Pacific (APAC)

China
Japan
India
South Korea
Rest of Asia-Pacific

Middle East and Africa (MEA)

Saudi Arabia
U.A.E
South Africa
Rest of MEA

South America

Argentina
Brazil
Chile
Rest of South America

Primary Research Interviews Breakdown

Needle Market Size

1. Research Overview

1.1. The Report Offers
1.2. Market Coverage
1.2.1. By Type
1.2.2. By Product Type
1.2.3. By Application
1.2.4. By End-use Industry
1.2.5. By Region
1.3. Research Phases
1.4. Limitations
1.5. Market Methodology
1.5.1. Data Sources
1.5.1.1. Primary Research
1.5.1.2. Secondary Research
1.5.2. Methodology
1.5.2.1. Data Exploration
1.5.2.2. Forecast Parameters
1.5.2.3. Data Validation
1.5.2.4. Assumptions
1.5.3. Study Period & Data Reporting Unit

2. Executive Summary

3. Industry Overview

3.1. Industry Dynamics
3.1.1. Market Growth Drivers
3.1.2. Market Restraints
3.1.3. Key Market Trends
3.1.4. Major Opportunities
3.2. Industry Ecosystem
3.2.1. Porter’s Five Forces Analysis
3.2.2. Recent Development Analysis
3.2.3. Value Chain Analysis
3.3. Competitive Insight
3.3.1. Competitive Position of Industry Players
3.3.2. Market Attractive Analysis
3.3.3. Market Share Analysis

4. Global Market Estimate and Forecast

4.1. Global Market Overview
4.2. Global Market Estimate and Forecast to 2030

5. Market Segmentation Estimate and Forecast

5.1. By Type
5.1.1. Core Laboratory Diagnostics
5.1.1.1. Market Definition
5.1.1.2. Market Estimation and Forecast to 2030
5.1.2. POC Testing
5.1.2.1. Market Definition
5.1.2.2. Market Estimation and Forecast to 2030
5.1.3. Molecular Diagnostics
5.1.3.1. Market Definition
5.1.3.2. Market Estimation and Forecast to 2030
5.1.4.  Unmanned Aerial Vehicle
5.1.4.1. Market Definition
5.1.4.2. Market Estimation and Forecast to 2030
5.2. By Product Type
5.2.1. Consumables
5.2.1.1. Market Definition
5.2.1.2. Market Estimation and Forecast to 2030
5.2.2. Instruments
5.2.2.1. Market Definition
5.2.2.2. Market Estimation and Forecast to 2030
5.2.3. Software
5.2.3.1. Market Definition
5.2.3.2. Market Estimation and Forecast to 2030
5.3  By Application
5.3.1. Oncology/Cancer
5.3.1.1. Market Definition
5.3.1.2. Market Estimation and Forecast to 2030
5.3.2. Infectious Diseases
5.3.2.1. Market Definition
5.3.2.2. Market Estimation and Forecast to 2030
5.3.3.  Diabetes
5.3.2.1. Market Definition
5.3.2.2. Market Estimation and Forecast to 2030
5.3.4.  By Cardiology
5.3.3.1. Market Definition
5.3.3.2. Market Estimation and Forecast to 2030
5.4.  By End-Use Industry
5.4.1.  Hospitals and Clinics
5.4.1.1. Market Definition
5.4.1.2. Market Estimation and Forecast to 2030
5.4.2.  Diagnostic Laboratories
5.4.2.1. Market Definition
5.4.2.2. Market Estimation and Forecast to 2030
5.4.3.  Academic and Research Institutions
5.4.3.1. Market Definition
5.4.3.2. Market Estimation and Forecast to 2030
5.4.4.  Other End-Use Industries
5.4.4.1. Market Definition
5.4.4.2. Market Estimation and Forecast to 2030

6. North America Market Estimate and Forecast

6.1. By Type
6.2. By Product Type
6.3. By Application
6.4. By End-Use Industry
6.5.1. Market Estimate and Forecast
6.5.2. Canada Market Estimate and Forecast
6.5.3. Mexico Market Estimate and Forecast

7. Europe Market Estimate and Forecast

7.1. By Type
7.2. By Product Type
7.3. By Application
7.4. By End-Use Industry
7.5.1. Germany Market Estimate and Forecast
7.5.2. France Market Estimate and Forecast
7.5.3. U.K. Market Estimate and Forecast
7.5.4. Italy Market Estimate and Forecast
7.5.5. Spain Market Estimate and Forecast
7.5.6. Rest of Europe Market Estimate and Forecast

8. Asia-Pacific Market Estimate and Forecast

8.1. By Type
8.2. By Product Type
8.3. By Application
8.4. By End-Use Industry
8.4. By Country – China, Japan, India, South Korea, and Rest of Asia-Pacific
8.5.1. China Market Estimate and Forecast
8.5.2. Japan Market Estimate and Forecast
8.5.3. India Market Estimate and Forecast
8.5.4. South Korea Market Estimate and Forecast
8.5.5. Singapore Market Estimate and Forecast
8.5.6. Rest of Asia-Pacific Market Estimate and Forecast

9. Rest of the World (RoW) Market Estimate and Forecast

9.1. By Type
9.2. By Product Type
9.3. By Application
9.4. By End-Use Industry
9.5. By Country – Brazil, Saudi Arabia, South Africa, U.A.E., and Other Countries
9.5.1. Brazil Market Estimate and Forecast
9.5.2. Saudi Arabia Market Estimate and Forecast
9.5.3. South Africa Market Estimate and Forecast
9.5.4. Other Countries Market Estimate and Forecast

10. Company Profiles

10.1. Abbott Laboratories
10.1.1. Snapshot
10.1.2. Overview
10.1.3. Offerings
10.1.4. Financial Insight
10.1.5. Recent Developments
10.2. Fulcrum BioEnerg Inc.
10.2.1. Snapshot
10.2.2. Overview
10.2.3. Offerings
10.2.4. Financial Insight
10.2.5. Recent Developments
10.3. BioMérieux SA
10.3.1. Snapshot
10.3.2. Overview
10.3.3. Offerings
10.3.4. Financial Insight
10.3.5. Recent Developments
10.4. Bio-Rad Laboratories
10.4.1. Snapshot
10.4.2. Overview
10.4.3. Offerings
10.4.4. Financial Insight
10.4.5. Recent Developments
10.5. Danaher Corporation
10.5.1. Snapshot
10.5.2. Overview
10.5.3. Offerings
10.5.4. Financial Insight
10.5.5. Recent Developments
10.6. F. Hoffmann-La Roche Ltd.
10.6.1. Snapshot
10.6.2. Overview
10.6.3. Offerings
10.6.4. Financial Insight
10.6.5. Recent Developments
10.7. Illumina
10.7.1. Snapshot
10.7.2. Overview
10.7.3. Offerings
10.7.4. Financial Insight
10.7.5. Recent Developments
10.8. QIAGEN N.V.
10.8.1. Snapshot
10.8.2. Overview
10.8.3. Offerings
10.8.4. Financial Insight
10.8.5. Recent Developments
10.9. Shenzhen Mindray Bio-Medical Electronics Co.
10.9.1. Snapshot
10.9.2. Overview
10.9.3. Offerings
10.9.4. Financial Insight
10.9.5. Recent Development

10.10. Siemens Healthineers AG
10.10.1. Snapshot
10.10.2. Overview
10.10.3. Offerings
10.10.4. Financial Insight
10.10.5. Recent Developments
10.11. Thermo Fisher Scientific Inc.
10.11.1. Snapshot
10.11.2. Overview
10.11.3. Offerings
10.11.4. Financial Insight
10.11.5. Recent Developments
10.12. Wama Diagnostica
10.12.1. Snapshot
10.12.2. Overview
10.12.3. Offerings
10.12.4. Financial Insight
10.12.5. Recent Developments
  10.13.   Wiener Laboratorios SAIC
10.13.1. Snapshot
10.13.2. Overview
10.13.3. Offerings
10.13.4. Financial Insight
10.13.5. Recent Developments
  10.14.   QuidelOrtho Corporation
10.14.1. Snapshot
10.14.2. Overview
10.14.3. Offerings
10.14.4. Financial Insight
10.14.5. Recent Developments
  10.15.   Agilent Technologies Inc.
10.15.1. Snapshot
10.15.2. Overview
10.15.3. Offerings
10.15.4. Financial Insight
10.15.5. Recent Developments
  10.16.   DiaSorin S.p.A.
10.16.1. Snapshot
10.16.2. Overview
10.16.3. Offerings
10.16.4. Financial Insight
10.16.5. Recent Developments
11. Appendix

11.1. Exchange Rates
11.2. Abbreviations

Note: Financial insight and recent developments of different companies are subject to the availability of information in the secondary domain.

List of Tables

Table 1 Types
Table 2 Study Periods
Table 3 Data Reporting Unit

Table 4 Global Next-Generation IVD Market Size, by Type, 2018-2023 (USD Billion)
Table 5 Global Next-Generation IVD Market Size, by Type, 2025-2030 (USD Billion)
Table 6 Global Next-Generation IVD Market Size, by Product Type, 2018-2023 (USD Billion)
Table 7 Global Next-Generation IVD Market Size, by Product Type, 2025-2030 (USD Billion)
Table 8 Global Next-Generation IVD Market Size, by Application, 2018-2023 (USD Billion)
Table 9 Global Next-Generation IVD Market Size, by Application, 2025-2030 (USD Billion)
Table 8 Global Next-Generation IVD Market Size, by End-use Industry, 2018-2023 (USD Billion)
Table 9 Global Next-Generation IVD Market Size, by End-use Industry, 2025-2030 (USD Billion)
Table 10 Global Next-Generation IVD Market Size, by Region, 2018-2023 (USD Billion)
Table 11 Global Next-Generation IVD Market Size, by Region, 2025-2030 (USD Billion)
Table 12 North America Next-Generation IVD Market Size, by Type, 2018-2023 (USD Billion)
Table 13 North America Next-Generation IVD Market Size, by Type, 2025-2030 (USD Billion)
Table 14 North America Next-Generation IVD Market Size, by Product Type, 2018-2023 (USD Billion)
Table 15 North America Next-Generation IVD Market Size, by Product Type, 2025-2030 (USD Billion)
Table 16 North America Next-Generation IVD Market Size, by Application, 2018-2023 (USD Billion)
Table 17 North America Next-Generation IVD Market Size, by Application, 2025-2030 (USD Billion)
Table 16 North America Next-Generation IVD Market Size, by End-use Industry, 2018-2023 (USD Billion)
Table 17 North America Next-Generation IVD Market Size, by End-use Industry, 2025-2030 (USD Billion)
Table 18 North America Next-Generation IVD Market Size, by Country, 2018-2023 (USD Billion)
Table 19 North America Next-Generation IVD Market Size, by Country, 2025-2030 (USD Billion)
Table 20 Europe Next-Generation IVD Market Size, by Type, 2018-2023 (USD Billion)
Table 21 Europe Next-Generation IVD Market Size, by Type, 2025-2030 (USD Billion)
Table 22 Europe Next-Generation IVD Market Size, by Product Type, 2018-2023 (USD Billion)
Table 23 Europe Next-Generation IVD Market Size, by Product Type, 2025-2030 (USD Billion)
Table 24 Europe Next-Generation IVD Market Size, by Application, 2018-2023 (USD Billion)
Table 25 Europe Next-Generation IVD Market Size, by Application, 2025-2030 (USD Billion)
Table 26 Europe Next-Generation IVD Market Size, by End-use Industry, 2018-2023 (USD Billion)
Table 27 Europe Next-Generation IVD Market Size, by End-use Industry, 2025-2030 (USD Billion)
Table 28 Europe Next-Generation IVD Market Size, by Country, 2018-2023 (USD Billion)
Table 29 Europe Next-Generation IVD Market Size, by Country, 2025-2030 (USD Billion)
Table 30 Asia-Pacific Next-Generation IVD Market Size, by Type, 2018-2023 (USD Billion)
Table 31 Asia-Pacific Next-Generation IVD Market Size, by Type, 2025-2030 (USD Billion)
Table 32 Asia-Pacific Next-Generation IVD Market Size, by Product Type, 2018-2023 (USD Billion)
Table 33 Asia-Pacific Next-Generation IVD Market Size, by Product Type, 2025-2030 (USD Billion)
Table 34 Asia-Pacific Next-Generation IVD Market Size, by Application, 2018-2023 (USD Billion)
Table 35 Asia-Pacific Next-Generation IVD Market Size, by Application, 2025-2030 (USD Billion)
Table 36 Asia-Pacific Next-Generation IVD Market Size, by Country, 2018-2023 (USD Billion)
Table 37 Asia-Pacific Next-Generation IVD Market Size, by Country, 2025-2030 (USD Billion)
Table 38 RoW Next-Generation IVD Market Size, by Type, 2018-2023 (USD Billion)
Table 39 RoW Next-Generation IVD Market Size, by Type, 2025-2030 (USD Billion)
Table 40 RoW Next-Generation IVD Market Size, by Product Type, 2018-2023 (USD Billion)
Table 41 RoW Next-Generation IVD Market Size, by Product Type, 2025-2030 (USD Billion)
Table 42 RoW Next-Generation IVD Market Size, by Application, 2018-2023 (USD Billion)
Table 43 RoW Next-Generation IVD Market Size, by Application, 2025-2030 (USD Billion)
Table 44 RoW Next-Generation IVD Market Size, by End-use Industry, 2018-2023 (USD Billion)
Table 45 RoW Next-Generation IVD Market Size, by End-use Industry, 2025-2030 (USD Billion)
Table 46 RoW Next-Generation IVD Market Size, by Country, 2018-2023 (USD Billion)
Table 47 RoW Next-Generation IVD Market Size, by Country, 2025-2030 (USD Billion)
Table 48 Snapshot – Abbott Laboratories
Table 49 Snapshot – Becton
Table 50 Snapshot – Dickinson and Company
Table 51 Snapshot – BioMérieux SA
Table 52 Snapshot – Bio-Rad Laboratories
Table 53 Snapshot – Danaher Corporation
Table 54 Snapshot – F. Hoffmann-La Roche Ltd.
Table 55 Snapshot – Illumina
Table 56 Snapshot – QIAGEN N.V.
Table 57 Snapshot – Shenzhen Mindray Bio-Medical Electronics Co.
Table 58 Snapshot – Siemens Healthineers
Table 59 Snapshot – Thermo Fisher Scientific Inc.
Table 60 Snapshot – Wama Diagnostica
Table 61 Snapshot – Wiener Laboratorios SAIC
Table 62 Snapshot – QuidelOrtho Corporation
Table 63 Snapshot – Agilent Technologies Inc.
Table 64 Snapshot – DiaSorin S.p.A.

List of Figures

Figure 1 Market Coverage
Figure 2 Research Phases
Figure 3 Secondary Types for Different Parameters
Figure 4 Methodology
Figure 5 Data Mining & Exploration
Figure 6 Data Triangulation
Figure 7 Assumptions for Market Estimation and Forecast
Figure 8 Market Synopsis
Figure 9 Global Next-Generation IVD Market - Growth Drivers and Restraints
Figure 10 Competitive Benchmark
Figure 11 Global Next-Generation IVD Market Highlight
Figure 12 Global Next-Generation IVD Market Size, by Type, 2018 - 2030 (USD Billion)
Figure 13 Global Next-Generation IVD Market Size, by Product Type 2018 - 2030 (USD Billion)
Figure 14 Global Next-Generation IVD Market Size, by Application 2018 - 2030 (USD Billion)
Figure 15 Global Next-Generation IVD Market Size, by End-use Industry 2018 - 2030 (USD Billion)
Figure 16 Global Next-Generation IVD Market Size, by Region, 2018 - 2030 (USD Billion)
Figure 17 North America Next-Generation IVD Market Highlight
Figure 18 North America Next-Generation IVD Market Size, by Type, 2018 - 2030 (USD Billion)
Figure 19 North America Next-Generation IVD Market Size, by Product Type 2018 - 2030 (USD Billion)
Figure 20 North America Next-Generation IVD Market Size, by Application 2018 - 2030 (USD Billion)
Figure 21 North America Next-Generation IVD Market Size, by End-use Industry 2018 - 2030 (USD Billion)
Figure 22 North America Next-Generation IVD Market Size, by Country, 2018 - 2030 (USD Billion)
Figure 23 Europe Next-Generation IVD Market Highlight
Figure 24 Europe Next-Generation IVD Market Size, by Type, 2018 - 2030 (USD Billion)
Figure 25 Europe Next-Generation IVD Market Size, by Product Type 2018 - 2030 (USD Billion)
Figure 26 Europe Next-Generation IVD Market Size, by Application 2018 - 2030 (USD Billion)
Figure 27 Europe Next-Generation IVD Market Size, by End-use Industry 2018 - 2030 (USD Billion)
Figure 28 Europe Next-Generation IVD Market Size, by Country, 2018 - 2030 (USD Billion)
Figure 29 Asia-Pacific Next-Generation IVD Market Highlight
Figure 30 Asia-Pacific Next-Generation IVD Market Size, by Type, 2018 - 2030 (USD Billion)
Figure 31 Asia-Pacific Next-Generation IVD Market Size, by Product Type 2018 - 2030 (USD Billion)
Figure 32 Asia-Pacific Next-Generation IVD Market Size, by Application 2018 - 2030 (USD Billion)
Figure 33 Asia-Pacific Next-Generation IVD Market Size, by End-use Industry 2018 - 2030 (USD Billion)
Figure 34 Asia-Pacific Next-Generation IVD Market Size, by Country, 2018 - 2030 (USD Billion)
Figure 35 RoW Next-Generation IVD Market Highlight
Figure 36 RoW Next-Generation IVD Market Size, by Type, 2018 - 2030 (USD Billion)
Figure 37 RoW Next-Generation IVD Market Size, by Product Type 2018 - 2030 (USD Billion)
Figure 38 RoW Next-Generation IVD Market Size, by Application 2018 - 2030 (USD Billion)
Figure 39 RoW Next-Generation IVD Market Size, by End-use Industry 2018 - 2030 (USD Billion)
Figure 40 RoW Next-Generation IVD Market Size, by Country, 2018 - 2030 (USD Billion)

Purchase Options

Enquire Before Buying

Ask for Customization

Latest Report

Research Methodology

Desk Research / Pilot Interviews
Build Market Size Model
Research and Analysis
Final Deliverabvle

Connect With Our Sales Team